Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells

Biochemical Pharmacology

Volumn 52, Issue 3, 1996, Pages 433-439

  Pietsch, Angelika ^a   Erl, Wolfgang ^a   Lorenz, Reinhard L ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

CD36; HMG CoA inhibitor; lovastatin; monocytic cells; oxLDL; scavenger receptor

Indexed keywords

APOLIPOPROTEIN B100; CD36 ANTIGEN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MEVALONIC ACID; MEVINOLIN; OXIDIZED LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; ATHEROSCLEROSIS; CELL LINE; CELL SELECTION; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPLETION; DRUG ANTAGONISM; FEEDBACK SYSTEM; FLUORESCENCE; FOAM CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030576663     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00245-6     Document Type: Article

References (39)

1. 1. Kelly MJ and Roberts SM, Combating cholesterol. Nature 373: 192-193, 1995.
2. 2. Ross R, The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
3. 3. Scandinavian Simvastatin Survival Study, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344: 1383-1389, 1994.
4. 4. Goldstein JL and Brown MS, Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
5. 5. Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL and Brown MS, Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptors in livers of hamsters and rabbits. Proc Natl Acad Sci USA 83: 8370-8374, 1986.
6. 6. Keidar S, Aviram M, Maor I, Oiknine J and Brook G, Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. Br J Clin Pharmac 38: 513-519, 1994.
7. 7. Levine GL, Keaney JF and Vita JA, Cholesterol reduction in cardiovascular disease. N Engl J Med 332: 512-521, 1995.
8. 8. Giroux LM, Davignon J and Naruszewicz M, Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1165: 335-338, 1993.
9. 9. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthsarathy S, Carew TE, Butler S, Witztum JL and Steinberg D, Evidence for the presence of oxidatively modified low density in atherosclerotic lesions of rabbit and man. J Gin Invest 84: 1086-1095, 1989.
10. 10. Matsumoto A, Naito M, Itakura H, Ikemoto S, Asaoka H, Hayakawa I, Kanamori H, Abruatani H, Takaku F, Suzuki H, Kobari Y, Miyai T, Takahashi K, Cohen EH, Wydro R, Housman DE and Kodama T, Human macrophage scavenger receptors: Primary structure, expression, and localization in atheroscerotic lesions. Proc Natl Acad Sci USA 87: 9133-9137, 1990.
11. 11. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT and Protter AA, CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268: 11811-11816, 1993.
12. 12. Acton SL, Scherer PE, Lodish HF and Krieger M, Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem 269: 21001-21009, 1994.
13. 13. Greenwalt DE, Lipsky RE, Ockenhouse CF, Ikeda H, Tandon NN and Jamieson GA, Membrane glycoprotein CD36: A review of its roles in adherence, signal transduction, and transfusion medicine. Blood 80: 1105-1115, 1992.
14. 14. Oquendo P, Hundt E, Lawier J and Seed B, CD36 directly mediates cytoaderence of plasmodium falciparum parasitized erythrocytes. Cell 58: 95-101, 1989.
15. 15. Asch AS, Barnwell J and Nachman RL, Isolation of the thrombospondin membrane receptor. J Clin Invest 79: 1054-1061, 1987.
16. 16. Diaz-Ricart M, Tandon NN, Carretero M, Ordinas A, Bastida E and Jamieson GA, Platelets lacking functional CD36 (glycoprotein IV) show reduced adhesion to collagen in flowing whole blood. Blood 82: 491-496, 1993.
17. 17. Nozaki S, Yamashita S, Kashiwagi H, Tomiyama Y, Nakata A, Nakagawa T, Ishigami M, Mivagawa J, Takemura K, Kurata Y and Matsuzawa Y, The role of CD36 on foam cell formation-reduced uptake of oxidized LDL in monocyte-macrophages from CD36 deficient patients. Circulation 90: I-190, 1994.
18. 18. Pietsch A, Weber C, Goretzki M, Weber PC and Lorenz RL, N-3 but not n-6 fatty acids reduce the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Cell Biochem Funct 13: 211-216, 1995.
19. 19. Schulz T, Scheithe R, Schiffel H, Hrboticky N, and Lorenz RL, Preserved antioxidative defence of lipoproteins in renal failure and during hemodialysis. Am J Kidney Dis 25: 564-571, 1995.
20. 20. Scheithe R, Hrboticky N, Ziegler-Heitbrock HWL and Weber PC, Receptor-specific uptake and degradation of acetylated, oxidized and native LDL in the human monocytic Mono Mac 6sr cell line. Biochem Biophys Res Commun 202: 334-339, 1994.
21. 21. Markwell MAK, Haas SM, Bieber LL and Telbert NEA, Modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87: 206-210, 1987.
22. 22. Weber C, Aepfelbacher M, Haag H, Ziegler-Heitbrock HWL and Weber PC, Tumor necrosis factor induces enhanced responses to platelet activation factor and differentiation in human monocytic Mono Mac 6 cells. Eur J Immunol 23: 852-859, 1993.
23. 23. Goldstein JL and Russel DW, The human LDL Receptor: A cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 39: 27-38, 1984.
24. 24. Ponte P, Ng SY, Engel J, Gunning P and Kedes L, Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 12: 1687-1969, 1984.
25. 25. Gaus H, Lipford GB, Wagner H and Heeg K, Quantitative analysis of lymphokine mRNA expression by a nonradioactive method using PCR and anion exchange chromatography. J Immunol Meth 158: 229-236, 1993.
26. 26. DiCorleto PE and da la Motte CA, Characterization of the adhesion of the human monocytic cell line U937 to cultured endothelial cells. J Clin Invest 75: 1153-1161, 1985.
27. 27. Öberg F, Botling J and Nilsson K, Macrophages and the cytokine network. Transplant Proc 25: 2044-2047, 1993.
28. 28. Quinn MT, Parthasarathy S and Steinberg D, Lysophosphatidylcholine: a chemotactic factor for human monocytes and ist potential role in atherogenesis. Proc Natl Acad Sci USA 85: 2805-2809, 1988.
29. 29. Nicholson AC, Frieda S, Pearce A and Silvenstein R, Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Arterioscler Thromb Vasc Biol 15: 269-275, 1995.
30. 30. Brown MS and Goldstein JL, A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47, 1986.
31. 31. Brown MS and Goldstein JL, Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell 6: 307-316, 1975.
32. 32. Armesilla AL and Vegas MA, Structural organization of the gene for human CD36 glycoprotein. J Biol Chem 269: 18985-18991, 1994.
33. 33. Albers-Schonberg G, Joshua H, Lopez MB, Hensens OD, Springer JP, Chen J, Ostrove S, Hoffman CH, Alberts AW and Patchett AA, Dihydromevinolin, a potent hypocholesteremic metabolite produced by aspergillus terreus. J Antibiot 34: 507-512, 1981.
34. 34. Alberts AW, Discovery, biochemistry and biology of lovastatin. Am J Cardiol 62: 10J-15J, 1988.
35. 35. McDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, Alberts AW and Bokelman DL, Preclinical evaluation of lovastatin. Am J Cardiol 62: 16J-27J, 1988.
36. 36. Stubbs RJ, Schwartz M and Bayne WF, Determination of mevinolin and mevinolinic acid in plasma and bile by reversed-phase high-performance liquid chromatography. J Chromatog 383: 438-443, 1986.
37. 37. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN and Sugermann A, Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 30: 1128-1135, 1990.
38. 38. Goldstein JL, Ho YK, Basu SK and Brown MS, Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 76: 333-337, 1979.
39. 39. The MAAS Investigators, Effect of simvastatin on coronary atheroma, the multicenter anti-atheroma study (MAAS). Lancet 344: 633-638, 1994.